No Data
No Data
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Announces Target Price $166
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Wells Fargo Adjusts Price Target on Johnson & Johnson to $170 From $152, Keeps Equalweight Rating
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis
Express News | Johnson & Johnson - Tremfya Shows Less Structural Damage Progression at Week 24